The Technical Analyst
Bio Path Holdings Inc [BPTH]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Bio Path Holdings Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
7.28% $3.24
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.44 mill |
| EPS: | -33.63 |
| P/E: | -0.100 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 0.754 mill |
| Avg Daily Volume: | 0.0280 mill |
| RATING 2024-04-17 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.100 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.100 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.964 (-39.37%) $-1.276 |
| Date: 2024-04-17 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.40 - 4.08 ( +/- 26.02%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-05-02 | Cleaver Heath | Buy | 10 000 | Common Stock Option (right to buy) |
| 2023-05-02 | Aubert Paul | Buy | 10 000 | Common Stock Option (right to buy) |
| 2023-05-02 | Sherwood Aline | Buy | 10 000 | Common Stock Option (right to buy) |
| 2023-05-02 | Morris Douglas P | Buy | 13 000 | Common Stock Option (right to buy) |
| 2023-05-02 | Nielsen Peter Henry | Buy | 105 000 | Common Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 100.00 |
| Last 88 transactions |
| Buy: 10 429 808 | Sell: 661 335 |
Forecast:
16:00 - $3.29
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.29
Forecast 2: 16:00 - $3.29
Forecast 3: 16:00 - $3.29
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.24 (7.28% ) |
| Volume | 0.702 mill |
| Avg. Vol. | 0.0280 mill |
| % of Avg. Vol | 2 504.92 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BPTH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BPTH
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Latest Press Releases
2024-04-15 07:00:00 - Press Release
Bio-path Holdings Expands Global Patent Portfolio
Builds on global intellectual property portfolio to protect dnabilize® platform builds on global intellectual property portfolio to protect dnabilize® platform
2024-04-02 07:00:00 - Press Release
Bio-path Holdings Provides 2024 Clinical And Operational Update
Houston, april 02, 2024 (globe newswire) -- bio-path holdings, inc., (nasdaq:bpth), a biotechnology company leveraging its proprietary dnabilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today provides a clinical development and operational update for 2024. “the new year is off to a strong start as we build off positive data generated in 2023 that compel us to advance these studies as quickly as possible and to file for regulatory designations that could accelerate our path to approval,” said peter h.
2024-03-27 16:43:00 - Press Release
Stonegate Capital Partners Updates Coverage On Bio-path Holdings, Inc. (bpth) Q4 23
Dallas, texas--(newsfile corp. - march 27, 2024) - bio-path holdings, inc. (nasdaq: bpth): stonegate capital partners updates coverage on bio-path holdings, inc. (nasdaq: bpth) for q4 2023. to view the full announcement, including downloadable images, bios, and more, click here.
2024-03-08 07:00:00 - Press Release
Bio-path Holdings Reports Full Year 2023 Financial Results
Houston, march 08, 2024 (globe newswire) -- bio-path holdings, inc., (nasdaq:bpth), a biotechnology company leveraging its proprietary dnabilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the year ended december 31, 2023 and provided an update on recent corporate developments. “2023 was a year of focused execution, as evidenced by the continued progress across our pipeline of dnabilize programs,” said peter nielsen, president and chief executive officer of bio-path holdings.
2024-03-01 07:00:00 - Press Release
Bio-path Holdings To Announce Fourth Quarter And Full Year 2023 Financial Results On March 8, 2024
Houston, march 01, 2024 (globe newswire) -- bio-path holdings, inc., (nasdaq: bpth) a biotechnology company leveraging its proprietary dnabilize® antisense rnai nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on friday, march 8, 2024 at 8:30 a.m. et to report financial results for the fourth quarter and full year ended december 31, 2023 and to provide a business overview.
Latest News
2024-04-04 19:14:00 - Market Watch
Bio-Path Holdings shares sink 6% after deal for at-the-market offering
Shares of Bio-Path Holdings BPTH, -0.06% fell late Thursday after the company said it had reached a deal for an at-the-market share offering.
2024-03-08 10:28:08 - Seeking Alpha
Bio-Path Holdings Inc. (BPTH) Q4 2023 Earnings Call Transcript
Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q4 2023 Results Conference Call March 8, 2024 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP, Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - Roth MKM Operator Good morning, ladies and gentlemen, and welcome to the Bio-Path Holdings Full Year 2023 Earnings Conference Call. [Operator Instructions] Please also note today's event is being recorded.
2024-03-01 07:00:00 - GlobeNewsWire
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 8, 2024 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2023 and to provide a business overview.
2023-11-15 17:28:05 - Seeking Alpha
Bio-Path Holdings, Inc. (BPTH) Q3 2023 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q3 2023 Earnings Call Transcript November 15, 2023 8:30 AM ET Company Participants Will O'Connor - IR, Stern IR Peter Nielsen - President and CEO Anthony Price - SVP of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Third Quarter 2023 Earnings Conference Call.
2023-11-08 07:00:00 - GlobeNewsWire
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
HOUSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Wednesday, November 15, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023 and to provide a business overview.
2023-09-08 16:01:00 - GlobeNewsWire
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
HOUSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright 25th Annual Global Investment Conference made available on Monday, September 11, 2023 at 7:00 a.m. ET.
2023-08-15 13:44:07 - Seeking Alpha
Bio-Path Holdings, Inc. (BPTH) Q2 2023 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings Second Quarter 2023 Earnings Conference Call.
2023-08-08 07:00:00 - GlobeNewsWire
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, August 15, 2023 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2023 and to provide a business overview.
2023-06-26 09:17:11 - InvestorPlace
Why Is Bio-Path (BPTH) Stock Down 12% Today?
Bio-Path (NASDAQ: BPTH ) stock is sliding lower on Monday after the company announced a proposed public share offering. Bio-Path has yet to reveal the major details of its planned public offering.
2023-05-12 10:06:37 - Seeking Alpha
Bio-Path Holdings, Inc. (BPTH) Q1 2023 Earnings Call Transcript
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2023 Earnings Conference Call.